Syed Ullah, MD
Adult Medicine · Decatur, GANPI 1033498118
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 202 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$633
- AbbVie$425
- Lilly USA, LLC$325
- AstraZeneca$294
- GSK$258
- Abbott$205
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 37 | $633 |
| AbbVie | 25 | $425 |
| Lilly USA, LLC | 21 | $325 |
| AstraZeneca | 19 | $294 |
| GSK | 11 | $258 |
| Abbott | 11 | $205 |
| Regeneron Healthcare Solutions, Inc. | 12 | $198 |
| Shield Therapeutics Inc | 10 | $195 |
| Amarin Pharma, Inc. | 8 | $144 |
| Novo Nordisk | 8 | $138 |
| Exact Sciences | 4 | $87 |
| Bayer | 3 | $57 |
| Astellas Pharma US Inc | 3 | $50 |
| Merck | 3 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Asahi Intecc USA, Inc. | 1 | $36 |
| Nabriva Therapeutics, PLC | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 2 | $29 |
| Pfizer | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Linus Health, Inc. | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Electromed, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$3,536 in reported general payments places this provider in the 80th percentile of 43 adult medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $73,313 |
| JanuviaSitagliptin Phosphate | 35 | $41,272 |
| Diclofenac Sodium | 130 | $33,212 |
| FarxigaDapagliflozin Propanediol | 16 | $25,989 |
| MounjaroTirzepatide | 14 | $17,551 |
| JardianceEmpagliflozin | 11 | $16,904 |
| MyrbetriqMirabegron | 16 | $11,894 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,326 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,233 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,216 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,864 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 138 | $3,844 |
| Novolog FlexpenInsulin Aspart | 13 | $3,607 |
| Gabapentin | 149 | $2,091 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 14 | $1,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $138 | $73,31354 claims |
| MerckJanuvia | $41 | $41,27235 claims |
| AstraZenecaFarxiga, Symbicort | $294 | $31,22236 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $325 | $19,52828 claims |
| Boehringer IngelheimJardiance | $14 | $16,90411 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $11,89416 claims |
| GSKTrelegy Ellipta | $258 | $11,32618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 adult medicine providers in Georgia.
Other adult medicine in Decatur
- Tony BullonDecatur$19
- Michael CohenPooler$14K
- Jinne RichardsAlbany$11K
- Charles WilliamsAlpharetta$10K
- Kenneth JonesUnion City$9K
- Katherine McClellanRinggold$7K
- Ewaul PersaudSmyrna$6K
- Jenna Barnes CaronDalton$5K
- Alana VilladaBuford$4K
- Wylie NewtonGainesville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.